Descriptive study of the parkinsonian population in the north of France: Epidemiological analysis and healthcare consumption

Revue neurologique
N CarriereL Defebvre

Abstract

The "neurodegenerative diseases plan" under elaboration for the Hauts-de-France region requires better knowledge of the patient population and care pathways. In France, the prevalence of Parkinson's disease (PD) has been estimated from cohorts to be about 1-3 per 1000 inhabitants, but exhaustive data are scarce for the general population. The purpose of this study was to evaluate the prevalence of PD in the Hauts-de-France region and to assess PD-related healthcare consumption. A descriptive study was conducted to identify the parkinsonian population in the Hauts-de-France region (including the administrative districts of Pas-de-Calais and Picardie) for the year 2014. Parkinsonian patients were identified from health insurance fund reimbursement data using the following criteria: (i) reimbursement for a PD-specific medication; (ii) attribution of long-duration disease status coded as PD; (iii) hospital stay with PD diagnosis in the standard discharge report contained in the French medico-economic database on hospital activity (PMSI). The raw prevalence of PD in the region was 5.03 per 1000 inhabitants aged 20 years and older. The standardized prevalence by health territory ranged from 4.0 to 9.0 per 1000 inhabitants aged 20 yea...Continue Reading

References

Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·A ChiòD Schiffer
Oct 26, 2000·Brain : a Journal of Neurology·A Schrag, N Quinn
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Feb 7, 2002·Pharmacoepidemiology and Drug Safety·D A van de VijverA de Boer
Jun 21, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sonja von CampenhausenRichard Dodel
Jan 19, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Katia NoyesAndrew W Dick
Sep 26, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Nicholas R Szumski, Eric M Cheng
Nov 21, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Edward J NewmanDonald G Grosset
Apr 2, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S Perez-LloretUNKNOWN COPARK Study Group
May 25, 2011·American Journal of Epidemiology·Frédéric MoisanAlexis Elbaz
Oct 17, 2012·Annals of Neurology·Alastair J NoyceAnette Schrag
Nov 30, 2012·Journal of Neurology, Neurosurgery, and Psychiatry·Anna BjornsdottirElias Olafsson
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
May 21, 2014·JAMA Neurology·Santiago Perez-LloretOlivier Rascol
Jul 1, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Tamara PringsheimThomas D L Steeves
Nov 13, 2014·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P BlinN Moore
Jan 1, 2016·Revue neurologique·A ElbazF Moisan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Epidemiology of Aging

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here